Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
National Cancer Institute (NCI)
University of Florida
Emory University
Eli Lilly and Company
M.D. Anderson Cancer Center
Seattle Children's Hospital
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Baylor College of Medicine
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Seattle Children's Hospital
Seattle Children's Hospital
Milton S. Hershey Medical Center
Baylor College of Medicine
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
Nationwide Children's Hospital
Memorial Sloan Kettering Cancer Center
Baylor College of Medicine
Foghorn Therapeutics Inc.
Ipsen
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Ipsen
Memorial Sloan Kettering Cancer Center
Ipsen
Masonic Cancer Center, University of Minnesota
University of Alabama at Birmingham
Emory University
Florida International University
Dana-Farber Cancer Institute
Emory University
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
National Cancer Institute (NCI)